Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply.

Kaye, Keith S; McLeod, Sarah M; O'Donnell, John P; Altarac, David

Kaye, Keith S; McLeod, Sarah M; O'Donnell, John P; Altarac, David.

Affiliation

Kaye KS; Division of Allergy, Immunology and Infectious Diseases, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA. Electronic address: kk1116@rwjms.rutgers.edu.
McLeod SM; Entasis Therapeutics, Waltham, MA, USA.
O'Donnell JP; Entasis Therapeutics, Waltham, MA, USA.
Altarac D; Entasis Therapeutics, Waltham, MA, USA.

Lancet Infect Dis ; 23(8): e275-e276, 2023 08.

Article in En | MEDLINE | ID: mdl-37442148

Subject(s)

Acinetobacter baumannii; Acinetobacter calcoaceticus; Humans; Sulbactam/therapeutic use; Anti-Bacterial Agents/therapeutic use; Microbial Sensitivity Tests

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acinetobacter calcoaceticus / Acinetobacter baumannii Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2023 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google